CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 72 enrolled
Drug / intervention
Liposomal bupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05537883
NCT05537883Phase 1Completed
CompareCT.gov

Single Blinded Randomized Trial of Transversus Abdominis Plane Block Using Liposomal Bupivacaine in Metabolic and Bariatric Surgery Patients

Wake Forest University Health Sciences·interventional·Posted Sep 13, 2022·Updated Jun 11, 2025

In Brief

A Phase 1 clinical trial evaluating Liposomal bupivacaine and Bupivacaine Injection for Morbid Obesity and Bariatric Surgery Candidate. Completed, enrolled 72 participants across 1 site.

Detailed Summary

To investigate if laparoscopic Transversus Abdominis Plane (TAP) block using plain bupivacaine is equivalent to using liposomal bupivacaine in patients undergoing metabolic and bariatric surgery. The study will see if the plain bupivacaine group will be equivalent in terms of length of stay, Morphine Milligram Equivalents, Pain scores and patient satisfaction, but cost less.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMorbid Obesity, Bariatric Surgery Candidate
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedSep 13, 2022
Enrollment StartNov 29, 2022
Primary CompletionDec 7, 2023
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 3.8 years ago

Interventions

Liposomal bupivacainedrug

Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with liposomal bupivacaine

Bupivacaine Injectiondrug

Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with plain bupivacaine